

November 11, 2024

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers, Dalal
Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Subject: Press Release – Orchid Pharma Limited (“the Company”)

Dear Sir/Madam,

In accordance to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, kindly find enclosed the Press Release titled “**Orchid Pharma reports strong Q2 performance driven by new product milestones**”.

You are requested to take the above information on record.

Thanking You,
For **Orchid Pharma Limited**

Kapil Dayya
Company Secretary & Compliance Officer

Encl. As Above

Press Release

Orchid Pharma reports strong Q2 performance driven by new product milestones

Q2 results show 26% y-o-y PAT growth, driven by strategic initiatives for market expansion

New Delhi, 11 November 2024: Orchid Pharma Ltd., a leading pharmaceutical company headquartered in Chennai, today announced its Quarter 2 financial results for fiscal year 2024-25, demonstrating continued growth in PAT (Profit After Tax) at 26%, highlighting a strong growth trajectory fuelled by expanding sales, operational efficiency, and path breaking product. The reported increase in Q2 2024-25 sales is compared to the same period in the previous year i.e. 2023-24

Orchid Pharma's sales reached ₹222.7 crores, with EBITDA at ₹37.5 crores. Reflecting a solid performance for the first half of FY2025 (H1), the company's cumulative sales amounted to ₹467.1 crores, a notable 22% year-over-year increase compared to H1 FY2024. EBITDA for H1 rose to ₹78.6 crores, underscoring the effectiveness of Orchid's focus on cost control, productivity, and efficiency gains.

Commenting on the results, **Manish Dhanuka, Managing Director, Orchid Pharma** said: *"Our growth is a testament to disciplined operational execution and the momentum from our strategic business development initiatives like the newly launched Orchid AMS. The positive trajectory is proof of our commitment to driving sustainable, profitable growth."*

This quarter, Orchid Pharma achieved key milestones with 7ACA project and the Indian launch of ORBLICEF, its innovative Enmetazobactam-Cefepime drug, marking it as the first Indian-discovered drug now commercialized in the EU and approved in the U.S. Backed by a marketing partnership with CIPLA and promising initial results on Indian strains, ORBLICEF is set to make a significant impact on healthcare outcomes. Orchid Pharma also launched the Orchid AMS division, aimed at enhancing its antimicrobial stewardship initiatives, further solidifying its commitment to addressing global health challenges and advancing responsible use of antibiotics. Additionally, the sales of Enmetazobactam have commenced in Europe and Orchid anticipates further growth in the U.S., signaling progress in its global expansion efforts.

Orchid Pharma also successfully broke ground on its 7ACA project, as planned, on Ganesh Chaturthi, an auspicious day. Despite initial delays due to extended rains, the project is now advancing rapidly, and Orchid is excited to continue driving this significant development forward.

With strong Q2 results, a promising product pipeline, and strategic investments in capacity and partnerships, Orchid Pharma is well-positioned to capitalize on emerging opportunities. The company's progress exemplifies its dedication to operational excellence and disciplined execution, creating substantial value for stakeholders and strengthening its standing in the pharmaceutical industry.

About Orchid Pharma Limited:

Established in 1992 as an export-oriented unit (EOU), Orchid Pharma Ltd. (Orchid) is a vertically integrated Company spanning the entire pharmaceutical value chain with established credentials in research, manufacturing, and marketing.

Orchid, is the only Indian Pharmaceutical Company, to ever have invented a New Chemical Entity (NCE, also colloquially called New Drug). The molecule is out licensed (on Royalty model) and now approved in US and Europe.

Orchid is a pioneer in Production of Quality Cephalosporins especially the Sterile Products, for which it is the one out of the only three USFDA approved facilities in the world, and the only one from India. Besides this, the facility has other approvals like EU GMP, ANVISA and PMDA.